Poolbeg Pharma (LON:POLB) Stock Falls 0.8% – Time to Sell?

Poolbeg Pharma PLC (LON:POLB)’s share price dropped 0.8% during mid-day trading on Tuesday. The stock traded as low as GBX 6.10 and last traded at GBX 6.20. 585,462 shares were traded during trading, a decline of 71% from the average daily volume of 2,029,141 shares. The stock had previously closed at GBX 6.25.

Analyst Ratings Changes

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, September 24th.

Poolbeg Pharma Stock Performance

The stock has a market capitalization of £50.39 million, a PE ratio of -8.35 and a beta of 1.83. The business’s 50-day moving average price is GBX 7.93 and its 200 day moving average price is GBX 6.73.

Poolbeg Pharma (LON:POLB) last announced its earnings results on Tuesday, September 29th. The company reported GBX (0.28) earnings per share for the quarter. As a group, equities research analysts predict that Poolbeg Pharma PLC will post -0.68 earnings per share for the current year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.